Persistent trophoblasic gestational disease: retrospective study about 55 cases at the National Institute of Oncology from 2000 to 2008

摘要

Abstract Introduction: Persistent trophoblastic disease is curable and chemosensitive with a cure rate of up to 90% even at a metastatic stage. The aim of this retrospective study is to highlight different aspects of epidemiological, clinical, therapeutic treatment of persistent gestational trophoblastic disease (MTGP) in Moroccan patients through a series of 55 cases collected at the National Institute of Oncology between 2000 and 2008.Materials and methods: We collected for each patient, the different epidemiological, clinical and therapeutic features. Results: The mean age was 37.8 years. Clinical aspects were dominated by bleeding and pelvic pain. There were 19 cases of invasive mole and 34 cases of choriocarcinoma. 41.8% had in their antecedents a hydatidiform mole. All patients were evaluable and were graded according to the score of FIGO 2000, 70.9% were found to be at high risk. Treatment consisted of chemotherapy based on methotrexate or cisplatin. The overall survival rate was 81.82% and median survival was 152.2 months (? 9.8 months). Survival according to chemotherapy regimen based or not on platinum showed a statistically significant difference (P = 0.019).Conclusion: Given these data, a first-line chemotherapy based on platinum regimen in high-risk patients could be an effective and tolerable option if there is any contra indication or unavailability of methotrexate. Other prospective trials should evaluate these two options.